Attendees at FDA’s meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees in late July will be armed with the agency’s 374-page “brief”-ing on a possible Risk Evaluation and Mitigation Strategy (REMS) for prescription opioids.
Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179